Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

120 participants · First posted May 18, 2022

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

30 participants · First posted Oct 30, 2024

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

42 participants · First posted Oct 11, 2023

POLQ inhibitor(AstraZeneca)

POLB-003

POLB 001

POLY MEDICURE LIMITED

India

Poly Pharmaceuticals Inc

United States

Pola Chemical Industries, Inc.

Japan

UCLA Researchers Present Breakthrough 177Lutetium-PSMA Therapy Results for Recurrent Prostate Cancer at ASTRO 2025

Comparative Analysis of PARP Inhibitors in BRCA-Mutated Ovarian Cancer Shows Similar Efficacy and Toxicity

PARP Inhibitors Show Similar Efficacy in BRCA-Mutated Ovarian Cancer, Cost-Effectiveness Varies